Asia Pacific in vitro diagnostics (IVD) market will grow by 7.8% annually with a total addressable market cap of $303,673.6 million over 2022-2031, driven by the increasing prevalence of chronic diseases along with the growing geriatric population, burgeoning demand for automation in diagnostics, the rising development of condition-specific treatment and booming awareness regarding personalized medicines, emergence of minimally invasive and non-invasive diagnostics tools & techniques, the rising healthcare expenditure, and rise in the demand for POC testing.
Highlighted with 35 tables and 64 figures, this 138-page report Asia Pacific In Vitro Diagnostics (IVD) Market 2021-2031 by Product (Instruments & Devices, Reagents & Kits, Software & Services), Technology (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics), Sample Type (Blood, Mucus, Urine), Application (Infectious Diseases, Diabetes, Cancer/Oncology), End User (Diagnostic Labs, Hospitals and Clinics, Homecare, POC), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific in vitro diagnostics (IVD) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific in vitro diagnostics (IVD) market in every aspect of the classification from perspectives of Product, Technology, Sample Type, Application, End User, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Instruments & Devices
o Disposable IVD Devices
o Reusable IVD Devices
Reagents & Kits
Software & Services
Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Clinical Chemistry
Molecular Diagnostics
Immuno Diagnostics
Hematology
Tissue Diagnostics
Microbiology
Coagulation and Hemostasis
Urinalysis
Other Technologies
By Sample Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Blood
Mucus
Urine
Other Sample Types
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Infectious Diseases
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Drug Testing
HIV/AIDS
Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Diagnostic Laboratories
Hospitals and Clinics
Homecare Settings
Point-of-Care (POC) Settings
Other End Users
Geographically, the following national/local markets are fully investigated:
Japan
China
South Korea
Australia
India
Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Application and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories, Inc.
Agilent Technologies, Inc.
Arkray Inc.
Becton, Dickinson and Company
Biomerieux SA
Bio-Rad Laboratories Inc.
Danaher Corporation
DiaSorin SpA (Luminex Corporation)
Epic Systems Corporation
F. Hoffmann-La Roche Ltd.
Genpact Limited
Grifols SA
IBM Corporation
Mckesson Corporation
Ortho Clinical Diagnostics Inc.
Qiagen NV
Quest Diagnostics Inc.
Quidel Corporation
Roche Diagnostics
Siemens Healthineers
Sysmex Corporation
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
